Crystalline Phosphate Drug Forms Balancing Solubility and IV Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate face challenges in achieving rapid therapeutic effectiveness due to limited solubility and stability, particularly in aqueous solutions, which complicates parenteral administration in conditions like stroke and traumatic brain injury.
Innovation Solution
The development of crystalline forms, such as Crystalline Form 1, a hemi-ethyl acetate solvate, which offers improved solubility and stability, allowing for rapid achievement of therapeutically effective amounts of N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide, suitable for IV administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If prodrug salt forms are used to improve solubility, then solubility in aqueous media is improved, but stability is worsened due to hydrolysis in the solid state
Solution Approach 1:
The patent applies parameter changes by modifying the physical form of the compound from amorphous prodrug salts to crystalline forms. Specifically, Crystalline Form 1 (the hemi-ethyl acetate solvate) and other anhydrous crystalline forms are designed to maintain stable molecular structures that resist hydrolysis while providing adequate solubility through controlled crystal lattice arrangements and solvate formation.
Solution Approach 2:
The patent employs composite material strategies by creating solvate forms where the active compound is combined with solvent molecules (ethyl acetate, acetonitrile, dioxane, or methanol) in defined stoichiometric ratios within the crystal structure. These solvate complexes provide both structural stability and controlled solubility characteristics that neither component achieves alone.
2Speed
If rapid therapeutic effectiveness is achieved through high solubility formulations, then onset of action is improved, but stability during storage and administration is worsened
Solution Approach 1:
The patent utilizes parameter changes by developing crystalline forms with specific solubility characteristics. Crystalline Form 1 and other anhydrous crystalline forms are engineered to dissolve at controlled rates that enable rapid therapeutic onset while maintaining structural integrity during storage and handling, thus balancing speed of action with stability.
3Quantity of substance
If amorphous forms are used to improve solubility, then dissolution rate is improved, but manufacturing precision and stability are worsened
Solution Approach 1:
The patent applies parameter changes by transitioning from amorphous to crystalline forms, which provides well-defined melting points, solubility characteristics, and physical properties. This enables precise manufacturing control through conventional pharmaceutical processing techniques while maintaining stable, reproducible performance.
Solution Approach 2:
The patent employs composite material strategies by creating solvate forms with specific solvent-to-solute ratios (e.g., hemi-ethyl acetate solvate with 0.5:1 ratio). These defined composite structures provide consistent physical properties that facilitate precise manufacturing and quality control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Crystalline Form 1 provides enhanced solubility and stability, facilitating rapid and effective IV delivery of the therapeutic agent, addressing the limitations of previous forms in achieving desired therapeutic concentrations.
Implementation Method 1
Crystalline Form 1, a hemi-ethyl acetate solvate, which offers improved solubility and stability
Data Source
AI summary
Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals.